ASF Standards · Hospital · Standard 12
Standard 12 — Organ & Tissue Transplant
Criteria in this standard
12.1 — Donor Consent Obtained Through a Process Independent of the Transplant Team
12.2 — Organ Allocation Follows a Transparent, Documented Protocol
12.3 — No Financial Incentive to Donor or Family
12.4 — Recipient Evaluation and Informed Consent Process
12.5 — Organ and Tissue Traceability, End to End
12.6 — Post-Transplant Follow-Up and Outcome Tracking
12.2 — Organ Allocation Follows a Transparent, Documented Protocol
12.3 — No Financial Incentive to Donor or Family
12.4 — Recipient Evaluation and Informed Consent Process
12.5 — Organ and Tissue Traceability, End to End
12.6 — Post-Transplant Follow-Up and Outcome Tracking
12.1
Donor Consent Obtained Through a Process Independent of the Transplant Team
Non-Negotiable
Donor or donor-family consent for organ or tissue donation is obtained through a process genuinely independent of the transplant team requesting the organ, with the independence structurally built in — not a theoretical separation undermined by the same staff being involved in both roles.
In plain terms: The person asking a family for consent to donate has no personal stake in whether they say yes — a genuine, structural separation from the team that would actually use the organ, not just a separation on paper.
| Facility category | Crisis | Transitional | Small | Standard |
|---|---|---|---|---|
| Applicability | Where applicable | Full | Full | Full |
Why this matters
This separation exists because a transplant team member, however well-intentioned, has an inherent conflict of interest when approaching a grieving family about donation — their professional investment in a successful transplant outcome is in direct tension with the family’s need for an uninfluenced decision. A theoretical separation, where staff are nominally distinct but still report through the same leadership or regularly interact professionally, doesn’t provide the genuine independence this criterion requires.
What good looks like
- The person obtaining consent is genuinely organizationally separate from the transplant team.
- A documented process ensures no transplant-team-affiliated person approaches the family.
- Staff can describe this separation clearly and confidently.
Common failure modes
- Separation exists in title only, with shared leadership or close working relationships.
- No documented process exists specifically preventing transplant-team contact with the family.
- Staff struggle to clearly explain how or why the separation functions.
Worked example
In practice
A hospital reviewing its donor consent process structure.
BeforeConsent conversations were handled by a coordinator who, while not a transplant surgeon, reported to the same department head as the transplant team and worked closely with them on a daily basis, creating a working relationship that undermined genuine independence.
ActionThe hospital restructured the consent coordination role to report through an entirely separate organizational line, with explicit policy prohibiting any transplant team member from being present during or involved in the consent conversation.
AfterThe Monitor reviewed the organizational structure and confirmed the consent coordinator’s reporting line was genuinely separate, with staff able to clearly describe the separation when asked. Criterion verified.
If you are starting from zero — do this first
- Map the current reporting structure for consent coordination versus the transplant team.
- Build a genuine organizational separation, not just a different job title.
- Write an explicit policy prohibiting transplant team involvement in consent conversations.
The most common mistake: Creating a distinct job title for consent coordination while leaving the reporting structure and working relationships functionally connected to the transplant team, which undermines the genuine independence this criterion requires.
Self-assessment questions
1. Is the person obtaining consent genuinely organizationally separate from the transplant team, not just nominally distinct while reporting to the same leadership? — A structural, not just a titular, separation is what actually protects against conflict of interest.
Evidence: Organizational structure documentation
Evidence: Organizational structure documentation
2. Is there a documented process ensuring the family or donor is never approached by someone with a direct stake in the transplant outcome? — The specific person requesting consent should have no personal or professional interest in a “yes” answer.
Evidence: Written policy
Evidence: Written policy
3. Can staff describe this separation clearly and confidently when asked? — If staff can’t articulate how the separation works, it may not be genuinely built into practice.
Evidence: Staff interview
Evidence: Staff interview
Common reasons for a PARTIAL answer
- A distinct role exists but shares leadership or close working relationships with the transplant team.
- Staff know a separation policy exists but can’t clearly explain how it functions.
Implementation plan
| When | What |
|---|---|
| Week 1 | Map the current consent coordination reporting structure. |
| Week 2 | Build a genuine organizational separation from the transplant team. |
| Week 3 | Write and distribute an explicit non-involvement policy. |
| Ongoing | Spot-check staff understanding of the separation. |
How the Monitor verifies this
| Method | What | Detail |
|---|---|---|
| DOCUMENT | Organizational structure review | Reviews the reporting structure to confirm genuine separation between consent coordination and the transplant team. |
Evidence base
World Health Organization. WHO Guiding Principles on Human Cell, Tissue and Organ Transplantation. Geneva: WHO; 2010 (updated 2024).
12.2
Organ Allocation Follows a Transparent, Documented Protocol
Non-Negotiable
Organ allocation decisions follow a written, transparent protocol based on clinical criteria, applied consistently, with any deviation from the standard protocol specifically documented and justified — not informal decisions vulnerable to undue influence.
In plain terms: Who gets an organ follows a real, written, consistent protocol based on clinical criteria — and any exception is specifically documented and justified, not an informal judgment call.
| Facility category | Crisis | Transitional | Small | Standard |
|---|---|---|---|---|
| Applicability | Where applicable | Full | Full | Full |
Why this matters
Informal allocation decisions, made case by case without a consistent written protocol, are genuinely vulnerable to undue influence — whether financial, social, or personal — precisely because there’s no documented standard to hold the decision against. An allocation protocol that exists on paper but isn’t actually available for independent review provides limited real transparency; genuine transparency means a decision can actually be examined after the fact, not merely that a document describing the intended process exists somewhere.
What good looks like
- A written protocol genuinely governs allocation decisions, applied consistently.
- Any deviation is specifically documented with a clear clinical justification.
- The protocol and decision record are available for independent review.
Common failure modes
- Allocation relies on informal clinical judgment applied case by case.
- Deviations from protocol happen without documented justification.
- The protocol exists but decision records aren’t genuinely accessible for review.
Worked example
In practice
A transplant program reviewing its allocation decision records.
BeforeA written allocation protocol existed, but several recent decisions deviated from it without any documented justification, with the deviations only discoverable by closely comparing the protocol’s stated criteria against actual outcomes.
ActionThe program built a required justification field for any protocol deviation, reviewed by a separate oversight committee, with all allocation decisions and justifications logged in a reviewable record.
AfterThe Monitor reviewed the allocation decision log and found a recent deviation with a clear, documented clinical justification reviewed by the oversight committee. Criterion verified.
If you are starting from zero — do this first
- Build or confirm a written allocation protocol based on clinical criteria.
- Build a required justification field for any protocol deviation.
- Build an independent review mechanism for allocation decisions.
The most common mistake: A protocol deviation occurring without a documented justification, discoverable only by closely comparing actual decisions against the protocol’s stated criteria, rather than being flagged and reviewed at the time it happens.
Self-assessment questions
1. Does a written protocol genuinely govern allocation decisions, not informal judgment applied case by case? — A written, consistent protocol is a specific, checkable safeguard against undue influence.
Evidence: Written allocation protocol
Evidence: Written allocation protocol
2. Is any deviation from the standard protocol specifically documented with a clear clinical justification? — An undocumented deviation is a specific, checkable gap that undermines the protocol’s purpose.
Evidence: Deviation justification record
Evidence: Deviation justification record
3. Is the allocation protocol and decision record available for independent review? — Genuine transparency means a decision can actually be reviewed, not just exist on paper.
Evidence: Reviewable decision log
Evidence: Reviewable decision log
Common reasons for a PARTIAL answer
- A protocol exists but deviations aren’t consistently documented.
- Decision records exist but aren’t genuinely accessible for independent review.
Implementation plan
| When | What |
|---|---|
| Week 1 | Confirm or build a written allocation protocol. |
| Week 2 | Build a required deviation justification field. |
| Week 3 | Build an independent review mechanism. |
| Ongoing | Audit allocation decisions periodically for protocol consistency. |
How the Monitor verifies this
| Method | What | Detail |
|---|---|---|
| DOCUMENT | Allocation decision log review | Reviews recent allocation decisions for protocol adherence and documented justification for any deviation. |
Evidence base
World Health Organization. WHO Guiding Principles on Human Cell, Tissue and Organ Transplantation. Geneva: WHO; 2010 (updated 2024).
12.3
No Financial Incentive to Donor or Family
Non-Negotiable
No financial payment or material incentive, beyond legitimate reimbursement of documented direct costs, is offered to a donor or donor family in connection with organ or tissue donation, with staff trained to recognize and refuse any such arrangement.
In plain terms: No payment or material incentive is ever offered for donation, beyond actual documented direct costs — and staff genuinely know the difference and know how to refuse an improper arrangement.
| Facility category | Crisis | Transitional | Small | Standard |
|---|---|---|---|---|
| Applicability | Where applicable | Full | Full | Full |
Why this matters
The prohibition on financial incentive for organ and tissue donation is a foundational, internationally recognized principle specifically protecting against exploitation, particularly of vulnerable individuals or families under financial pressure who might otherwise feel coerced toward a decision they wouldn’t otherwise make. The distinction between legitimate reimbursement of genuinely documented direct costs and a prohibited incentive needs to be concrete and well understood by staff, not left to individual judgment in a sensitive, emotionally charged moment.
What good looks like
- A clear, written policy explicitly prohibits incentive beyond legitimate cost reimbursement.
- Staff are trained to recognize the concrete distinction between reimbursement and incentive.
- A documented process exists for reporting any suspected violation.
Common failure modes
- No specific written prohibition exists beyond a general assumed understanding.
- Staff lack concrete training on what distinguishes reimbursement from incentive.
- No real reporting mechanism exists for a suspected violation.
Worked example
In practice
A hospital training new staff on donation-related policy.
BeforeStaff understood generally that payment for donation was prohibited, but had no specific training on what counted as legitimate documented cost reimbursement versus a prohibited incentive, leaving the distinction to individual judgment in the moment.
ActionThe hospital built specific training with concrete examples distinguishing legitimate reimbursement — documented travel or lodging costs directly tied to the donation process — from prohibited incentive, with a clear, anonymous reporting pathway for any suspected violation.
AfterThe Monitor interviewed staff and found they could clearly articulate the distinction with concrete examples, and confirmed the reporting pathway was known and accessible. Criterion verified.
If you are starting from zero — do this first
- Write a specific, explicit policy with concrete examples of the reimbursement/incentive line.
- Build training staff actually complete, not just a policy document distributed.
- Build a clear, accessible reporting pathway for suspected violations.
The most common mistake: Relying on a general, assumed understanding that payment is prohibited, without specific training giving staff concrete examples of what distinguishes legitimate cost reimbursement from a prohibited financial incentive.
Self-assessment questions
1. Is there a clear, written policy explicitly prohibiting financial incentive beyond legitimate documented cost reimbursement? — A specific, written prohibition, not an assumed understanding.
Evidence: Written policy
Evidence: Written policy
2. Are staff trained to recognize what counts as a legitimate reimbursement versus a prohibited incentive? — The distinction needs to be concrete and understood, not left to individual judgment in the moment.
Evidence: Training record with concrete examples
Evidence: Training record with concrete examples
3. Is there a documented process for reporting any suspected violation of this policy? — A real, actionable reporting pathway, not just a policy statement with no mechanism behind it.
Evidence: Reporting pathway documentation
Evidence: Reporting pathway documentation
Common reasons for a PARTIAL answer
- A policy exists but training lacks concrete, specific examples.
- A reporting pathway exists on paper but staff aren’t confident using it.
Implementation plan
| When | What |
|---|---|
| Week 1 | Write a specific policy with concrete reimbursement/incentive examples. |
| Week 2 | Build and deliver staff training on the policy. |
| Week 3 | Build a clear, accessible reporting pathway. |
| Ongoing | Refresh training periodically and verify reporting pathway awareness. |
How the Monitor verifies this
| Method | What | Detail |
|---|---|---|
| ASK | Staff interview | Asks staff to describe the reimbursement/incentive distinction with concrete examples. |
Evidence base
World Health Organization. WHO Guiding Principles on Human Cell, Tissue and Organ Transplantation. Geneva: WHO; 2010 (updated 2024).
12.4
Recipient Evaluation and Informed Consent Process
Core
Transplant recipients undergo a documented evaluation against clinical eligibility criteria, with genuine informed consent covering realistic outcomes, risks, and the source of the organ or tissue where legally and clinically relevant — not a general surgical consent treated as sufficient.
In plain terms: Recipients are genuinely evaluated against real clinical criteria, and their consent actually covers transplant-specific risks and outcomes — not a generic surgical consent form treated as covering everything.
| Facility category | Crisis | Transitional | Small | Standard |
|---|---|---|---|---|
| Applicability | Where applicable | Full | Full | Full |
Why this matters
A referral for transplant evaluation is a starting point, not a documented eligibility determination in itself — treating the two as equivalent overlooks the genuine clinical assessment this decision requires. A generic surgical consent form, while covering standard operative risks, doesn’t address the specific considerations unique to transplant — realistic graft survival rates, rejection risk, lifelong immunosuppression — which is why genuine, transplant-specific informed consent, with understanding actually verified rather than merely a signature obtained, matters here.
What good looks like
- Recipient evaluation against clinical eligibility criteria is actually documented.
- Informed consent genuinely covers transplant-specific outcomes and risks.
- The recipient’s understanding is genuinely verified, not just a signature obtained.
Common failure modes
- A referral is treated as equivalent to a documented eligibility determination.
- A generic surgical consent form is used without transplant-specific content.
- Consent is obtained as a signature with no genuine verification of understanding.
Worked example
In practice
A kidney transplant candidate’s evaluation and consent process.
BeforeThe candidate’s referral from their nephrologist was treated as sufficient eligibility documentation, with the hospital’s standard surgical consent form used, covering general operative risks but not specifically addressing graft survival rates or lifelong immunosuppression requirements.
ActionThe hospital built a specific transplant eligibility evaluation, documented separately from the referral, and a transplant-specific consent process including a teach-back verification step to confirm genuine understanding.
AfterThe Monitor reviewed a recent recipient’s file and found a documented eligibility evaluation distinct from the referral, transplant-specific consent content, and a teach-back verification record. Criterion verified.
If you are starting from zero — do this first
- Build a documented eligibility evaluation distinct from the referral.
- Build transplant-specific consent content, not a generic surgical form.
- Build a teach-back or equivalent understanding-verification step.
The most common mistake: Treating a physician’s referral for transplant evaluation as equivalent to a documented eligibility determination, and using a generic surgical consent form that doesn’t address the specific risks and realistic outcomes unique to transplant.
Self-assessment questions
1. Is recipient evaluation against clinical eligibility criteria actually documented, not assumed from referral alone? — A referral for transplant evaluation is not the same as a documented eligibility determination.
Evidence: Eligibility evaluation record
Evidence: Eligibility evaluation record
2. Does informed consent genuinely cover realistic outcomes and risks specific to transplant, not a generic surgical consent form? — Transplant carries specific risks and realistic outcome ranges that a generic surgical consent doesn’t address.
Evidence: Transplant-specific consent content
Evidence: Transplant-specific consent content
3. Is the recipient’s understanding genuinely verified, not just a signature obtained? — A signature confirms a form was signed, not that the content was genuinely understood.
Evidence: Understanding verification record
Evidence: Understanding verification record
Common reasons for a PARTIAL answer
- Consent covers transplant content but understanding isn’t actively verified.
- Eligibility evaluation happens but isn’t clearly documented separately from referral.
Implementation plan
| When | What |
|---|---|
| Week 1 | Build a documented eligibility evaluation process. |
| Week 2 | Build transplant-specific consent content. |
| Week 3 | Build an understanding-verification step into the consent process. |
| Ongoing | Spot-check recipient files for complete documentation. |
How the Monitor verifies this
| Method | What | Detail |
|---|---|---|
| DOCUMENT | Recipient file review | Checks for documented eligibility evaluation and transplant-specific consent with understanding verification. |
Evidence base
World Health Organization. WHO Guiding Principles on Human Cell, Tissue and Organ Transplantation. Geneva: WHO; 2010 (updated 2024).
12.5
Organ and Tissue Traceability, End to End
Core
Every organ or tissue is traceable through a documented chain of custody from donor to recipient, including handling, testing, and transport, with no gap in the record at any point in that chain.
In plain terms: Every organ or tissue can genuinely be traced, start to finish, with no missing link anywhere in the chain — retrievable on request, not just theoretically documented.
| Facility category | Crisis | Transitional | Small | Standard |
|---|---|---|---|---|
| Applicability | Where applicable | Full | Full | Full |
Why this matters
A single gap anywhere in the chain of custody — at handling, testing, or transport — undermines the entire purpose of traceability, since the whole value lies in being able to reconstruct the complete path with confidence. A general pass/fail log entry for testing and screening, rather than specific, retrievable results tied to that particular organ or tissue, provides considerably less genuine assurance than a detailed, organ-specific record.
What good looks like
- A continuous chain of custody record exists with no gap at any handling point.
- Specific testing and screening results are included, not a general log entry.
- The full chain can genuinely be reconstructed on request for a specific organ.
Common failure modes
- A gap exists in the record at one or more handling points.
- Testing records are a general pass/fail note rather than specific results.
- The chain is theoretically documented but difficult to actually reconstruct.
Worked example
In practice
A tissue bank reviewing its traceability record completeness.
BeforeAn attempt to reconstruct a specific tissue’s full chain of custody revealed a gap during the transport handoff between the recovery team and the processing lab, where no formal handoff record had been kept.
ActionThe tissue bank built a mandatory handoff record at every transfer point in the chain, with a barcode or equivalent tracking system ensuring no point in the process lacks a documented record.
AfterThe Monitor selected a specific tissue and successfully reconstructed its complete chain of custody from donor through to recipient, with no gap at any point. Criterion verified.
If you are starting from zero — do this first
- Attempt to reconstruct a specific organ or tissue’s full chain right now.
- Identify any gap points in the current process.
- Build a mandatory handoff record at every transfer point.
The most common mistake: A gap in the documented chain at a specific transfer point — often between teams or facilities — where no formal handoff record was kept, discovered only when someone actually attempts to reconstruct the full chain.
Self-assessment questions
1. Is there an actual, continuous chain of custody record, with no gap at any handling point? — A single gap in the chain undermines the entire traceability purpose.
Evidence: Chain of custody record
Evidence: Chain of custody record
2. Does the record include testing and screening results specific to that organ or tissue, not just a general log entry? — Specific, retrievable results, not a generic pass/fail note.
Evidence: Organ-specific testing record
Evidence: Organ-specific testing record
3. Can the full chain be reconstructed on request for a specific organ or tissue? — Genuinely retrievable on demand, not theoretically traceable but practically difficult to reconstruct.
Evidence: Live reconstruction exercise
Evidence: Live reconstruction exercise
Common reasons for a PARTIAL answer
- Most points are documented but one specific transfer point lacks a record.
- Records exist but take considerable effort to actually reconstruct.
Implementation plan
| When | What |
|---|---|
| Week 1 | Attempt to reconstruct a current chain and identify any gaps. |
| Week 2 | Build a mandatory handoff record at every transfer point. |
| Week 3 | Build or confirm a tracking system enabling quick reconstruction. |
| Ongoing | Periodically test reconstruction speed and completeness. |
How the Monitor verifies this
| Method | What | Detail |
|---|---|---|
| DOCUMENT | Live chain reconstruction | Selects a specific organ or tissue and attempts to reconstruct its full chain of custody on the spot. |
Evidence base
World Health Organization. WHO Guiding Principles on Human Cell, Tissue and Organ Transplantation. Geneva: WHO; 2010 (updated 2024).
12.6
Post-Transplant Follow-Up and Outcome Tracking
Standard
Transplant recipients are followed systematically after the procedure, with graft and patient outcomes tracked and reported, not lost to follow-up once the recipient is discharged from the immediate post-operative period.
In plain terms: Recipients are genuinely followed on a real schedule, with outcomes tracked across the whole program — not simply relying on the recipient to reach out if something’s wrong.
| Facility category | Crisis | Transitional | Small | Standard |
|---|---|---|---|---|
| Applicability | Where applicable | Full | Full | Full |
Why this matters
Relying on a recipient’s own initiative to seek follow-up, rather than a proactive, systematic schedule, risks losing track of patients precisely when ongoing monitoring for rejection or complications matters most. Outcomes scattered across individual, unconnected patient files, rather than genuinely aggregated and tracked, prevent the program from meaningfully monitoring its own overall performance over time — a capability that matters both for quality improvement and for honest accountability.
What good looks like
- A documented, systematic follow-up schedule exists, not informal recipient-initiated contact.
- Graft and patient outcomes are actually tracked and aggregated.
- A documented process exists for re-engaging a recipient lost to follow-up.
Common failure modes
- Follow-up depends on the recipient reaching out, not a proactive schedule.
- Outcomes exist in individual files but aren’t aggregated for program-level tracking.
- A recipient lost to follow-up is simply accepted, with no active re-engagement.
Worked example
In practice
A transplant program reviewing its follow-up completeness.
BeforeFollow-up largely depended on recipients scheduling their own appointments, with no proactive outreach, and graft outcome data existed scattered across individual patient charts with no program-level aggregation or tracking.
ActionThe program built a proactive follow-up schedule with automated reminders, an aggregated outcome tracking database, and a specific re-engagement protocol — including a direct outreach call — for any recipient who misses a scheduled follow-up.
AfterThe Monitor reviewed the aggregated outcome database and confirmed a recent re-engagement case where a missed follow-up triggered a successful outreach call bringing the recipient back into care. Criterion verified.
If you are starting from zero — do this first
- Build a proactive, systematic follow-up schedule, not recipient-initiated contact.
- Build an aggregated outcome tracking system across the program.
- Build a specific re-engagement protocol for missed follow-ups.
The most common mistake: Relying on recipients to schedule their own follow-up appointments rather than a proactive, systematic schedule, which risks losing track of patients precisely when ongoing monitoring matters most.
Self-assessment questions
1. Is there a documented, systematic follow-up schedule, not informal contact depending on the recipient’s own initiative? — A real, proactive schedule, not reliance on the recipient to seek follow-up themselves.
Evidence: Follow-up schedule
Evidence: Follow-up schedule
2. Are graft and patient outcomes actually tracked and aggregated, not scattered across individual, unconnected patient files? — Aggregated tracking enables the program to genuinely monitor its own outcomes over time.
Evidence: Aggregated outcome database
Evidence: Aggregated outcome database
3. Is there a documented process for what happens when a recipient is lost to follow-up? — A specific, active process for re-engagement, not simply accepting the loss.
Evidence: Re-engagement protocol
Evidence: Re-engagement protocol
Common reasons for a PARTIAL answer
- A follow-up schedule exists but outcomes aren’t aggregated at a program level.
- No active re-engagement process exists for recipients who miss follow-up.
Implementation plan
| When | What |
|---|---|
| Week 1 | Build a proactive follow-up schedule. |
| Week 2 | Build an aggregated outcome tracking system. |
| Week 3 | Build a re-engagement protocol for missed follow-ups. |
| Ongoing | Review program-level outcome trends periodically. |
How the Monitor verifies this
| Method | What | Detail |
|---|---|---|
| DOCUMENT | Outcome database review | Checks the aggregated outcome tracking system and reviews a specific missed-follow-up re-engagement case. |
Evidence base
World Health Organization. WHO Guiding Principles on Human Cell, Tissue and Organ Transplantation. Geneva: WHO; 2010 (updated 2024).